Amylyx Pharmaceuticals, Inc. (AMLX) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $11.00K; Additional Paid in Capital, Common StockUSD $1.08B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $19.00K; Retained Earnings (Accumulated Deficit)USD $-836.13M.
- 2026-03-31: Common Stock, Value, IssuedUSD $11.00K; Additional Paid in Capital, Common StockUSD $1.07B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $240.00K; Retained Earnings (Accumulated Deficit)USD $-792.71M.
- 2025-12-31: Common Stock, Value, IssuedUSD $11.00K; Additional Paid in Capital, Common StockUSD $1.06B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $404.00K; Retained Earnings (Accumulated Deficit)USD $-751.43M.
- 2025-09-30: Common Stock, Value, IssuedUSD $11.00K; Additional Paid in Capital, Common StockUSD $1.05B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $815.00K; Retained Earnings (Accumulated Deficit)USD $-718.43M.
Amylyx Pharmaceuticals, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|
| 2026-06-30 | $11.00K | $1.08B | $19.00K | $-836.13M | $239.17M | 3 month · $8.32M |
| 2026-03-31 | $11.00K | $1.07B | $240.00K | $-792.71M | $273.16M | 3 month · $6.12M |
| 2025-12-31 | $11.00K | $1.06B | $404.00K | $-751.43M | $305.26M | 12 month · $27.64M |
| 2025-09-30 | $11.00K | $1.05B | $815.00K | $-718.43M | $332.00M | 3 month · $7.08M |
| 2025-06-30 | $9.00K | $851.36M | $551.00K | $-684.04M | $167.88M | 3 month · $7.35M |
| 2025-03-31 | $9.00K | $844.01M | $0.00 | $-642.60M | $201.42M | 3 month · $6.83M |
| 2024-12-31 | $7.00K | $771.54M | $-92.00K | $-606.69M | $164.76M | 12 month · $33.04M |
| 2024-09-30 | $7.00K | $764.70M | $641.00K | $-569.15M | $196.20M | 3 month · $6.80M |
| 2024-06-30 | $7.00K | $757.84M | $-97.00K | $-496.44M | $261.31M | 3 month · $9.57M |
| 2024-03-31 | $7.00K | $748.25M | $-77.00K | $-423.74M | $324.44M | 3 month · $9.92M |
| 2023-12-31 | $7.00K | $738.18M | $197.00K | $-304.95M | $433.43M | 12 month · $37.55M |
| 2023-09-30 | $7.00K | $728.22M | $-151.00K | $-309.68M | $418.40M | 3 month · $10.28M |
| 2023-06-30 | $7.00K | $717.00M | $-72.00K | $-330.57M | $386.37M | 3 month · $10.05M |
| 2023-03-31 | $7.00K | $705.26M | $25.00K | $-352.65M | $352.65M | 3 month · $7.58M |
| 2022-12-31 | $7.00K | $694.91M | $-86.00K | $-354.22M | $340.61M | 12 month · $21.71M |
| 2022-09-30 | $6.00K | $456.26M | $-725.00K | $-311.52M | $144.03M | 3 month · $5.52M |
| 2022-06-30 | $6.00K | $450.74M | $-196.00K | $-257.76M | $192.79M | 3 month · $5.71M |
| 2022-03-31 | $6.00K | $444.78M | $-151.00K | $-203.69M | $240.95M | 3 month · $4.39M |
| 2021-12-31 | $1.00K | $4.67M | $9.00K | $-155.84M | $-151.17M | 12 month · $3.14M |
| 2021-09-30 | (m) | (m) | (m) | (m) | $-124.07M | 3 month · $802.00K |
| 2021-06-30 | (m) | (m) | (m) | (m) | $-101.89M | 3 month · $657.00K |
| 2021-03-31 | (m) | (m) | (m) | (m) | $-80.63M | 3 month · $586.00K |
| 2020-12-31 | (m) | (m) | (m) | (m) | $-66.72M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |